Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645317 | 1.00 | AKR1C3 (0.54) | AKR1C3PTGS2AKR1C2AKR1C1KMT2A | |
| SCHEMBL2646052 | 0.86 | KMT2A (0.47) | AKR1C3PTGS2KMT2A | |
| SCHEMBL2646055 | 0.86 | KMT2A (0.47) | AKR1C3PTGS2KMT2A | |
| SCHEMBL1581394 | 0.83 | KMT2A (0.44) | AKR1C3KMT2A | |
| SCHEMBL1581391 | 0.83 | KMT2A (0.44) | AKR1C3KMT2A | |
| SCHEMBL2646492 | 0.79 | AKR1C3 (0.57) | AKR1C3PTGS2AKR1C2AKR1C1KMT2A | |
| SCHEMBL2646494 | 0.79 | AKR1C3 (0.57) | AKR1C3PTGS2AKR1C2AKR1C1KMT2A | |
| SCHEMBL1581873 | 0.78 | KMT2A (0.47) | PTGS2KMT2A | |
| SCHEMBL1581870 | 0.78 | KMT2A (0.47) | PTGS2KMT2A | |
| SCHEMBL2646273 | 0.78 | AKR1C3 (0.64) | AKR1C3PTGS2AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |